|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0008976,
umls-concept:C0024485,
umls-concept:C0025677,
umls-concept:C0034656,
umls-concept:C0039103,
umls-concept:C0087111,
umls-concept:C0332120,
umls-concept:C0332287,
umls-concept:C0392756,
umls-concept:C0666743,
umls-concept:C0814225,
umls-concept:C1274040,
umls-concept:C1883709,
umls-concept:C2825032
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-1-13
|
|
pubmed:abstractText |
Anti-tumor necrosis factor alpha agents are among the most effective therapies for rheumatoid arthritis (RA). However, their optimal use is yet to be determined. This 12-month double-blind study attempted remission induction using standard therapy with or without infliximab in patients with early, poor-prognosis RA. The primary end point was synovitis (measured by magnetic resonance imaging [MRI]). Clinical observations continued to 24 months.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
27-35
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15641102-Antibodies, Monoclonal,
pubmed-meshheading:15641102-Antirheumatic Agents,
pubmed-meshheading:15641102-Arthritis, Rheumatoid,
pubmed-meshheading:15641102-Arthrography,
pubmed-meshheading:15641102-C-Reactive Protein,
pubmed-meshheading:15641102-Double-Blind Method,
pubmed-meshheading:15641102-Drug Therapy, Combination,
pubmed-meshheading:15641102-Follow-Up Studies,
pubmed-meshheading:15641102-Humans,
pubmed-meshheading:15641102-Magnetic Resonance Imaging,
pubmed-meshheading:15641102-Methotrexate,
pubmed-meshheading:15641102-Middle Aged,
pubmed-meshheading:15641102-Prognosis,
pubmed-meshheading:15641102-Quality of Life,
pubmed-meshheading:15641102-Remission Induction,
pubmed-meshheading:15641102-Severity of Illness Index,
pubmed-meshheading:15641102-Synovitis
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
|
|
pubmed:affiliation |
Academic Unit of Musculoskeletal Disease, First Floor, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
